Brief: Cti Biopharma Announces Initiation Of Phase 3 Pre-Vent Study Evaluating Pacritinib In Hospitalized Patients With Severe Covid-19
27/04/2020 12:35
April 27 (Reuters) - CTI Biopharma Corp CTIC.O :
* CTI BIOPHARMA ANNOUNCES INITIATION OF PHASE 3 PRE-VENT
STUDY
EVALUATING PACRITINIB IN HOSPITALIZED PATIENTS WITH SEVERE
COVID-19
* CTI BIOPHARMA - EXPECTS TO COMMENCE ENROLLMENT OF PRE-VENT
IN
MAY AT SITES IN U.S., EUROPE WITH DATA EXPECTED BY END OF 2020
Source text for Eikon: ID:nPn9w811Ta
Further company coverage: CTIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CTI Biopharma
See all newsBrief: CTI Biopharma Cancels 2023 Annual Meeting Of Stockholders
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners